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Jackson’s Families in Transition program provides resi-
dential treatment that benefits both substance abusers
and their children. 
While both authors share a focus on treating families,
they do so from opposite poles of the research-practice
spectrum, and bridging the distance is important to both.
Fals-Stewart’s intervention has performed well in studies
over 20 years, but has yet to be widely adopted by com-
munity clinics. Jackson’s program is highly successful
by its own internal measures, but wants research atten-
tion to sort out its critical components from others that
may expend resources without contributing significantly
to the desired outcomes.
Our “Science and Practice in Action” feature brings
together researchers and community providers affiliated
with the Community Anti-Drug Coalitions of America
(CADCA) in a dynamic and frank discussion of challenges,
methods, measures, and philosophies of drug abuse pre-
vention. We thank CADCA for co-sponsoring this con-
versation at its 14th annual National Leadership Forum.
As always, we hope you find useful information and
stimulating ideas in this issue of Science & Practice Perspectives.
David Anderson
Editor
National Institute on Drug Abuse
Stepping Into the Wide World
A
s I write this in June, it seems appropriate that in
this season of graduations we are publishing two
articles on buprenorphine. This medication is
emerging from the Nation’s research centers into the wider
world of community treatment settings, bearing a newly
conferred Food and Drug Administration approval for
treating opioid addiction. Researchers, clinicians, admin-
istrators, and policymakers are asking the same question
many proud and nervous parents ask as they watch their
children take diplomas in hand: Will it find its place in the
world and thrive?
Buprenorphine’s transition raises into high relief the
critical importance of continuity and interplay between
research and practice. For the new medication to have a
long, productive future, community programs need to
employ it appropriately, in line with the research results.
To assist programs in doing this, we are pleased to pub-
lish Hendrée Jones’s comprehensive practice-oriented
research review, “Practical Considerations for the Clinical
Use of Buprenorphine.” Fidelity to empirical knowledge
does not preclude creativity, as the three program direc-
tors on our response panel to Dr. Jones’s article demon-
strate. They have found ways to minimize side effects and
costs for their patients.
Mirroring the need for research awareness among the
practice community, buprenorphine now enters a phase
in which the critical buprenorphine research agenda reflects
experiences and questions arising out of its general use.
One such question, posed in “Community Treatment
Programs Take Up Buprenorphine,” is when, if ever, patients
may be able to terminate the use of the new medication
without jeopardizing their treatment gains. The answer is
of primary importance for Terry Horton of Phoenix House
in New York City and George Kolodner of Kolmac Clinic in
the Washington, D.C.-Maryland area. They are integrating
the use of buprenorphine into programs that up until now
have been completely abstinence based.
The two other peer-reviewed articles in this issue
describe drug abuse treatments that include family dynam-
ics among their intervention targets. William Fals-Stewart’s
behavioral couples therapy reduces intimate partner
violence and facilitates children’s behavioral adjust-
ment while helping patients achieve abstinence. Valera
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